Literature DB >> 1709331

Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics.

S O Frederiksen1, R Ekman, C G Gottfries, E Widerlöv, S Jonsson.   

Abstract

Postmortem investigations were performed in brains from 14 schizophrenic patients and 21 controls matched for age and autopsy latency. Concentrations of galanin, delta-sleep-inducing peptide (DSIP), corticotropin-releasing factor (CRF), arginine vasopressin (AVP), neuropeptide Y (NPY) and peptide YY (PYY) were determined in the hypothalamus and grey matter from the temporal cortex. A significant positive correlation between age and the concentrations of galanin and CRF was found in the controls. No sex differences were found except a higher mean of CRF in the hypothalamus of the women. In the temporal cortex of the schizophrenic brains, galanin, AVP, NPY and PYY were significantly reduced. DSIP reduction only bordered on significance. CRF was not reduced. Comparing neuroleptic-treated vs non-treated schizophrenics, the treatment factor could not explain the reduced concentrations of neuropeptides in the temporal lobe. A comparison of controls with schizophrenics showed no significant differences in hypothalamic neuropeptide concentrations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709331     DOI: 10.1111/j.1600-0447.1991.tb05539.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  17 in total

1.  Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders.

Authors:  Leah H Rubin; C Sue Carter; Jeffrey R Bishop; Hossein Pournajafi-Nazarloo; Lauren L Drogos; S Kristian Hill; Anthony C Ruocco; Sarah K Keedy; James L Reilly; Matcheri S Keshavan; Godfrey D Pearlson; Carol A Tamminga; Elliot S Gershon; John A Sweeney
Journal:  Schizophr Bull       Date:  2014-03-11       Impact factor: 9.306

Review 2.  Crossing the Worm-Brain Barrier by Using Caenorhabditis elegans to Explore Fundamentals of Human Psychiatric Illness.

Authors:  Donard S Dwyer
Journal:  Mol Neuropsychiatry       Date:  2018-01-11

3.  Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia.

Authors:  Hans-Gert Bernstein; Susan Müller; Hendrik Dobrowolny; Carmen Wolke; Uwe Lendeckel; Alicja Bukowska; Gerburg Keilhoff; Axel Becker; Kurt Trübner; Johann Steiner; Bernhard Bogerts
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-12-29       Impact factor: 5.270

4.  Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior.

Authors:  Victoria B Risbrough; Richard L Hauger; Amanda L Roberts; Wylie W Vale; Mark A Geyer
Journal:  J Neurosci       Date:  2004-07-21       Impact factor: 6.167

5.  Sexual dimorphism of stress response and immune/ inflammatory reaction: the corticotropin releasing hormone perspective.

Authors:  N V Vamvakopoulos
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

6.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

7.  Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis.

Authors:  Gursharan Chana; Chad A Bousman; Tammie T Money; Andrew Gibbons; Piers Gillett; Brian Dean; Ian P Everall
Journal:  Front Cell Neurosci       Date:  2013-06-26       Impact factor: 5.505

8.  Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology.

Authors:  D A Bangasser; A Curtis; B A S Reyes; T T Bethea; I Parastatidis; H Ischiropoulos; E J Van Bockstaele; R J Valentino
Journal:  Mol Psychiatry       Date:  2010-06-15       Impact factor: 15.992

9.  Novel animal models for studying complex brain disorders: BAC-driven miRNA-mediated in vivo silencing of gene expression.

Authors:  K A Garbett; S Horváth; P J Ebert; M J Schmidt; K Lwin; A Mitchell; P Levitt; K Mirnics
Journal:  Mol Psychiatry       Date:  2010-02-02       Impact factor: 15.992

10.  Schizophrenia pathophysiology: are we any closer to a complete model?

Authors:  Shaheen E Lakhan; Karen F Vieira
Journal:  Ann Gen Psychiatry       Date:  2009-05-15       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.